Focusing on Multiple Myeloma
The AACR is partnering with Takeda to support research to broaden our understanding of multiple myeloma and develop better treatments.
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell important for a healthy immune system. Over time, myeloma cells collect in the bone marrow, forming tumors in many of the body’s bones. These tumors may keep the bone marrow from making enough healthy blood cells and weaken the bone.
While the causes of
multiple myeloma are not fully understood, it is more common in older people, especially men, and African Americans. Some common symptoms include bone pain, weakness or fatigue, weight loss, frequent infections, and frequent urination.
The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program
estimates that more than 30,000 people living in the United States were diagnosed with multiple myeloma in 2016 and that more than 12,000 died of the disease.
March is Multiple Myeloma Awareness Month.
What is the AACR Doing in This Area?
In 2016, the AACR teamed up with
Takeda Oncology to offer two fellowships in the area of multiple myeloma research. The AACR-Takeda Oncology Fellowships in Multiple Myeloma Research are a joint effort to encourage and support a postdoctoral or clinical research fellow to conduct multiple myeloma-based research and to establish a successful career path in this field. The awardees were: Neelam Bhardwaj, PhD, for her study, "Generation of a Monoclonal Antibody Against VISTA for the Immunomodulatory Therapy of Multiple Myeloma;" and Barbara Castella, PhD, for her work, "Targeting Immune Inhibitory Pathways in the Bone Marrow of Myeloma Patients."
Takeda is a long-standing partner of the AACR, including as a
Leadership Sustaining Member. The company has donated nearly $4 million to support AACR initiatives since 1999.
The AACR's mission is to
prevent and cure all forms of cancer.